Views: 1,471 | Downloads:
30
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Topical Cyclosporine 0.5 Per Cent and Preservative-Free Ketorolac Tromethamine 0.5 Per Cent in Vernal Keratoconjunctivitis
Kosrirukvongs P 
,
Luengchaichawange C
,
Luengchaichawange C A Prospective, randomized cross-over study was conducted in patients with vernal kerato-
conjunctivitis, successfully treated with cyclosporine, to evaluate the efficacy of cyclosporine 0.5 per
cent compared with preservative-free ketorolac tromethamine 0.5 per cent. Patients received topical
cyclosporine in both eyes along with an assessment of the severity of their conjunctivitis. In cyclo-
sporine-treated patients, medication was discontinued 1 week before evaluation, then the medication
was started for 1 month, and washed out 1 week before the other drug was started. Symptoms of itch-
ing, foreign body sensation, tearing, photophobia, discharge, burning, conjunctival injection, chemosis,
giant papilla, keratopathy and intraocular pressure were evaluated weekly. There was a statistically
significant decrease in all symptoms of cyclosporine-treated eyes at day 7, 14 and 30 and all signs at
day 21 and 30. In ketorolac-treated eyes, there was a significant difference in itching, foreign body
sensation, photophobia, tearing, mucous discharge, all symptoms, chemosis, giant papillae and con-
junctival injection at day 7, and overall symptoms at day 14. Compared to cyclosporine-treated eyes
at day 7, kotorolac-treated eyes had significantly fewer symptoms. Topical cyclosporine 0.5 per cent
reduces symptoms and signs slower than preservative-free ketorolac tromethamine 0.5 per cent.
Key word : Vernal Keratoconjunctivitis, Topical Cyclosporine, Ketorolac Tromethamine
conjunctivitis, successfully treated with cyclosporine, to evaluate the efficacy of cyclosporine 0.5 per
cent compared with preservative-free ketorolac tromethamine 0.5 per cent. Patients received topical
cyclosporine in both eyes along with an assessment of the severity of their conjunctivitis. In cyclo-
sporine-treated patients, medication was discontinued 1 week before evaluation, then the medication
was started for 1 month, and washed out 1 week before the other drug was started. Symptoms of itch-
ing, foreign body sensation, tearing, photophobia, discharge, burning, conjunctival injection, chemosis,
giant papilla, keratopathy and intraocular pressure were evaluated weekly. There was a statistically
significant decrease in all symptoms of cyclosporine-treated eyes at day 7, 14 and 30 and all signs at
day 21 and 30. In ketorolac-treated eyes, there was a significant difference in itching, foreign body
sensation, photophobia, tearing, mucous discharge, all symptoms, chemosis, giant papillae and con-
junctival injection at day 7, and overall symptoms at day 14. Compared to cyclosporine-treated eyes
at day 7, kotorolac-treated eyes had significantly fewer symptoms. Topical cyclosporine 0.5 per cent
reduces symptoms and signs slower than preservative-free ketorolac tromethamine 0.5 per cent.
Key word : Vernal Keratoconjunctivitis, Topical Cyclosporine, Ketorolac Tromethamine
Download:
PDF